Calcium channel blockers for kidney protection

Area of Science:

• Nephrology
• Transplantation immunology
• Pharmacology

Background:

• Acute postischemic renal failure (ARF) is a significant complication in surgery and renal transplantation.
• Calcium channel blockers (CCBs) have shown promise in preventing ARF in experimental models when administered before ischemic injury.
• The potential benefit of CCBs administered after ischemic injury in ARF remains to be fully elucidated.

Purpose of the Study:

• To test the hypothesis that CCBs offer a beneficial effect when given after ischemic injury in renal transplantation.
• To evaluate the efficacy of diltiazem in preventing or ameliorating ARF in cadaveric kidney graft recipients.

Main Methods:

• A randomized trial involving 134 recipients of first or second cadaver grafts assigned to diltiazem pretreatment (DZ) or control (C) groups.
• Kidney grafts were reperfused with preservation fluid, with or without DZ. DZ patients received a 74-h infusion and subsequent oral administration until day 30.
• Immunosuppression included low-dose steroids and cyclosporine A (CSA), with CSA levels monitored by RIA.

Main Results:

• A significant reduction in ARF was observed in kidney grafts pretreated with diltiazem (DZ).
• ARF was defined as the need for dialysis within the first week post-transplantation.
• No significant differences were noted in donor demographics, HLA match, or ischemic times between groups.

Conclusions:

• Diltiazem pretreatment demonstrates a significant beneficial effect in reducing acute postischemic renal failure in kidney transplant recipients.
• These findings support the use of CCBs, like diltiazem, in the management of kidney transplantation to mitigate ischemic injury.
• Further research may explore optimal timing and dosage for CCB administration in preventing ARF.